Nicotinamide Riboside
Also known as: NR, Nicotinamide riboside chloride
An NAD precursor with measurable blood effects, a preliminary walking signal in artery disease and unfavorable Parkinson trial outcomes.

Nicotinamide riboside (NR) is a precursor used to raise NAD levels. Human blood measurements support that biochemical effect. Clinical outcomes vary by condition. A small peripheral artery disease trial found a preliminary walking signal, while the larger 2026 NOPARK trial's primary Parkinson disease outcome favored placebo. Broad anti-aging benefit remains unestablished.3, 1, 2
- A crossover study with 24 completers found that six weeks of NR raised blood NAD-related measures in middle-aged and older adults.3
- The 90-person NICE trial used a prespecified one-sided P < 0.10 criterion for its walking-distance endpoint.1
- NOPARK randomized 410 people with early Parkinson disease to NR or placebo for 52 weeks. Its primary clinical score favored placebo.2
What is Nicotinamide Riboside?
NR is a distinct nicotinamide-related compound. Supplements and safety assessments often specify its chloride salt. The body's ability to obtain nicotinamide from that preparation is relevant to vitamin metabolism, while each clinical trial addresses a separate outcome and population.4, 3
Where it comes from
Natural sources
- EFSA describes small amounts of NR in milk-derived foods, with limited information on other food sources.
How it's made
EFSA assessed a defined synthetic nicotinamide riboside chloride preparation.
What it does in products
Benefits
A preliminary walking signal in peripheral artery disease
limited evidenceThe result applies to one disease-specific phase II trial.1
At six months, NR alone improved six-minute walk distance by 17.6 m versus placebo, with a one-sided 90% confidence interval starting at 1.8 m and P = 0.08. This met the trial's exploratory significance criterion. Adding resveratrol produced no added benefit. Replication with conventional confirmatory testing remains important.
Evidence scope and limitations
Defined oral NR preparations, short-term blood NAD measurements, artery-disease walking outcomes and the 2026 early-Parkinson trial.
- NOPARK was checked through its original abstract. The accessible full-text record was under embargo, limiting this guide to reported results.
- NICE used a one-sided exploratory threshold. The walking result needs confirmation, and its secondary outcomes provide a narrower benefit picture.
- EFSA's opinion concerns specified proposed uses of NR chloride. Different preparations, high-dose combinations and broad longevity claims exceed that scope.
Evidence last checked: 2026-11-15
Side effects & safety
Safety considerations
- The amended 2019 EFSA assessment considered a specified chloride preparation at up to 230 mg/day for pregnant or lactating adults. That assessment has a defined food-use scope. FDA advises discussing supplements with a health professional during pregnancy and when taking medicines.
Amounts studied & product use
These figures describe research or common product use, not a personal dose or treatment recommendation.
In human trials and food-safety assessment
The 2018 crossover, NICE and NOPARK trials used 1,000 mg/day in their respective research protocols. EFSA's 2019 assessment evaluated proposed healthy-adult supplement use up to 300 mg/day, with a lower pregnancy/lactation amount. Trial exposure and food-safety assessment have different purposes. These figures describe their protocols and assessed uses.
Regulatory status
- U.S. dietary supplements generally enter the market without FDA premarket approval for efficacy. EFSA's 2019 opinion concerns the safety and nicotinamide bioavailability of a specified NR chloride preparation under proposed uses.
A higher NAD reading leaves clinical benefit unresolved
The 2018 trial established a biochemical response over six weeks. The later Parkinson trial measured a clinical endpoint over 52 weeks in a different population. In its primary analysis, the adjusted MDS-UPDRS difference was 2.72 points in the direction favoring placebo, with a 95% confidence interval of 0.47–4.98.
That finding argues against presenting NAD elevation as a reliable proxy for symptom improvement. It also leaves effects in healthy aging, other diseases and other NR formulations to be established by their own trials.
3, 2Frequently asked questions
Does adding resveratrol strengthen NR's walking result?
NICE included an NR-plus-resveratrol arm. The authors found no added benefit from that combination. The result comes from a small artery-disease trial and leaves other combinations unresolved.1
The bottom line
Judge NR by the clinical outcome and population studied, alongside its form-specific safety assessment.
References
- McDermott MM, Martens CR, Domanchuk KJ, et al.. Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial. Nature Communications (2024) · randomized trial · PMID 38871717; DOI 10.1038/s41467-024-49092-5; 15:5046; June 13, 2024; full methods and results checked, including the prespecified one-sided P < 0.10 criterion
- Brakedal B, Skeie GO, Derad C, et al.. Nicotinamide Riboside for Patients With Early-Stage Parkinson Disease: The NOPARK Randomized Clinical Trial. JAMA (2026) · randomized trial · PMID 42848371; DOI 10.1001/jama.2026.18828; NCT03568968; published online October 8, 2026; original abstract checked, full text under access embargo at this check
- Martens CR, Denman BA, Mazzo MR, et al.. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications (2018) · randomized trial · PMID 29599478; DOI 10.1038/s41467-018-03421-7; 9:1286; March 29, 2018; full crossover methods and adverse-event table checked
- EFSA Panel on Nutrition, Novel Foods and Food Allergens. Safety of nicotinamide riboside chloride as a novel food pursuant to Regulation (EU) 2015/2283 and bioavailability of nicotinamide from this source, in the context of Directive 2002/46/EC. EFSA Journal (2019) · safety assessment · DOI 10.2903/j.efsa.2019.5775; 17(8):5775; August 7, 2019, amended December 8, 2019; defined chloride preparation and population-specific proposed uses checked
- Questions and Answers on Dietary Supplements. U.S. Food and Drug Administration · government guidance · Undated current agency guidance checked November 15, 2026 for premarket review, pregnancy and medication-consultation framework
Revision history
- Initial AI-assisted source compilation with claim-level citations, formulation distinctions and explicit evidence limitations; not independent medical review.